Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorSun Yat-sen University
About this trial
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.
Eligibility criteria
Qualifiers
HCC diagnosed by histopathological examination or Guidelines for Diagnosis and Treatment of Primary Liver Cancer or the recurrent HCC after surgery;
age between 18 and 75 years;
Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage).
Locoregional therapy include TACE or HAIC, locoregional combined with Bevacizumab and PD1/L1 inhibitor as firstline therapy; non-firstline therapy (previous use of any systemic therapy but intolerant or drug resistant).
Disqualifiers
Cholangiocellular carcinoma (ICC).
Patients without image information should be excluded;
The survival or patients less than 3 months.
Serious medical comorbidities.
Trial design
Treatments tested in this trial
- Locoregional therapy
- Bevacizumab
- Atezolizumab
- Tislelizumab
- Toripalimab
- Sintilimab
- Camrelizumab
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov